keyword
MENU ▼
Read by QxMD icon Read
search

olodaterol

keyword
https://www.readbyqxmd.com/read/28057707/an-update-on-lama-laba-combinations-for-copd
#1
(no author information available yet)
The management of symptoms of chronic obstructive pulmonary disease (COPD) typically involves the use of inhaled long-acting bronchodilators. Previously, we have reviewed the long-acting muscarinic antagonists (LAMAs) ▼aclidinium,(1) ▼glycopyrronium,(2) tiotropium(3) and ▼umeclidinium,(4) and the long-acting beta2 agonists (LABAs) indacaterol,(5) ▼olodaterol,(6) and ▼vilanterol (in combination with fluticasone) in the management of COPD.(7) Four fixed-dose combinations of a LAMA with a LABA are now available, all indicated as maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD...
January 5, 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/28008243/efficacy-of-tiotropium-olodaterol-fixed-dose-combination-in-copd
#2
REVIEW
Eric Derom, Guy G Brusselle, Guy F Joos
Tiotropium-olodaterol, formulated in the Respimat soft-mist inhaler, is an inhaled fixed-dose combination (FDC) of a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA), commercialized under the name of Spiolto or Stiolto. The efficacy of tiotropium-olodaterol 5-5 μg once daily in adult patients with COPD was documented in eleven large, multicenter trials of up to 52 weeks duration. Tiotropium-olodaterol 5-5 μg not only improved spirometric values to a significantly greater extent than placebo but also resulted in statistically significant beneficial effects on dyspnea, markers of hyperinflation, use of rescue medication, health-related quality of life, and exercise endurance...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/27993292/long-term-general-and-cardiovascular-safety-of-tiotropium-olodaterol-in-patients-with-moderate-to-very-severe-chronic-obstructive-pulmonary-disease
#3
Roland Buhl, Sheldon Magder, Ulrich Bothner, Kay Tetzlaff, Florian Voß, Lazaro Loaiza, Claus F Vogelmeier, Lorcan McGarvey
BACKGROUND: Long-term safety, particularly cardiovascular safety, is of special interest in maintenance treatment of chronic obstructive pulmonary disease (COPD) with long-acting β2-agonists and long-acting muscarinic antagonists, given potential cardiovascular effects. METHODS: Two 52-week Phase III trials (TONADO(®)) investigated tiotropium/olodaterol (5/5 and 2.5/5 μg) versus tiotropium 2.5, 5 μg and olodaterol 5 μg. In a pre-specified safety analysis, investigator-reported treatment-emergent adverse events (AEs), electrocardiogram and laboratory data were pooled...
January 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/27971544/economic-evaluation-of-tiotropium-olodaterol-administrated-through-the-respimat-inhaler-as-maintenance-treatment-of-patients-with-chronic-obstructive-pulmonary-disease-copd-in-poland
#4
M Pawlik, P Karwala, A Zyla, M Parkitny, J Walczak, I Pieniazek, J Augustynska, A Zawodnik
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27957746/the-impact-of-olodaterol-on-the-risk-of-mortality-and-serious-adverse-events-a-systematic-review-and-meta-analysis
#5
Hyun Woo Lee, Hyung-Jun Kim, Chang-Hoon Lee
AIMS: Olodaterol is a novel inhaled long-acting beta-agonist (LABA) that showed efficacy as a bronchodilator for patients with chronic obstructive pulmonary disease (COPD) and asthma. However, it is unclear whether olodaterol reduces mortality; the safety issues of olodaterol have not been fully evaluated. METHODS: Randomized controlled trials comparing olodaterol with placebo for patients with COPD or asthma, which evaluated mortality or serious adverse events, were included...
December 13, 2016: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27920517/superiority-of-tiotropium-plus-olodaterol-in-comparison-with-salmeterol-plus-fluticasone
#6
COMMENT
Tomohiro Tamura, Hiroaki Satoh
No abstract text is available yet for this article.
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/27853383/uk-specific-cost-effectiveness-of-tiotropium-olodaterol-fixed-dose-combination-versus-other-lama-laba-combinations-in-patients-with-copd
#7
Abigail Tebboth, Andrew Ternouth, Nuria Gonzalez-Rojas
OBJECTIVE: The aim of this study is to assess the cost-effectiveness of other long-acting muscarinic antagonist + long-acting β2 agonist combinations in comparison with Spiolto(®) Respimat(®) (tiotropium + olodaterol fixed-dose combination [FDC]) for maintenance treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. METHODS: A previously published individual-level Markov model was adapted for the perspective of the UK health care system, in line with recommendations from the National Institute for Health and Care Excellence...
2016: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/27843306/efficacy-and-safety-of-tiotropium-olodaterol-maintenance-treatment-in-patients-with-copd-in-the-tonado-%C3%A2-and-otemto-%C3%A2-studies-a-subgroup-analysis-by-age
#8
Gary T Ferguson, Jill P Karpel, Emmanuelle Clerisme-Beaty, Lars Grönke, Florian Voß, Roland Buhl
BACKGROUND: Increasing age is associated with poor prognosis in patients with COPD. OBJECTIVE: This analysis from the replicate Phase III OTEMTO(®) and TONADO(®) studies examined the efficacy and safety of tiotropium, a long-acting anticholinergic, combined with olodaterol, a long-acting β2-agonist, compared to monotherapies and placebo in patients with COPD aged 40 years to <65 years, 65 years to <75 years, 75 years to <85 years, and ≥85 years. METHODS: In these double-blind, parallel-group, active-controlled, multicenter, randomized studies, patients received tiotropium + olodaterol 2...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/27703341/cost-effectiveness-and-budget-impact-of-the-fixed-dose-dual-bronchodilator-combination-tiotropium-olodaterol-for-patients-with-copd-in-the-netherlands
#9
Job Fm van Boven, Janwillem Wh Kocks, Maarten J Postma
PURPOSE: The fixed-dose dual bronchodilator combination (FDC) of tiotropium and olodaterol showed increased effectiveness regarding lung function and health-related quality of life in patients with chronic obstructive pulmonary disease (COPD) compared with the use of its mono-components. Yet, while effectiveness and safety have been shown, the health economic implication of this treatment is still unknown. The aim of this study was to assess the cost-utility and budget impact of tiotropium-olodaterol FDC in patients with moderate to very severe COPD in the Netherlands...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/27663386/eligibility-of-real-life-patients-with-copd-for-inclusion-in-trials-of-inhaled-long-acting-bronchodilator-therapy
#10
David M G Halpin, Marjan Kerkhof, Joan B Soriano, Helga Mikkelsen, David B Price
BACKGROUND: Management guidelines of chronic obstructive pulmonary disease (COPD) are mainly based on results of randomised controlled trials (RCTs), but some authors have suggested limited representativeness of patients included in these trials. No previous studies have applied the full range of selection criteria to a broad COPD patient population in a real-life setting. METHODS: We identified all RCTs of inhaled long-acting bronchodilator therapy, during 1999-2013, at ClinicalTrials...
September 23, 2016: Respiratory Research
https://www.readbyqxmd.com/read/27621608/the-efficacy-and-safety-of-combined-tiotropium-and-olodaterol-via-the-respimat-%C3%A2-inhaler-in-patients-with-copd-results-from-the-japanese-sub-population-of-the-tonado-%C3%A2-studies
#11
Masakazu Ichinose, Hiroyuki Taniguchi, Ayako Takizawa, Lars Grönke, Lazaro Loaiza, Florian Voß, Yihua Zhao, Yoshinosuke Fukuchi
BACKGROUND: The efficacy and safety of once-daily tiotropium + olodaterol (T+O) maintenance treatment was demonstrated in the large, multinational, replicate, randomized, Phase III, Tonado(®) 1 (NCT01431274) and 2 (NCT01431287) studies in patients with moderate to very severe COPD. However, there may be racial differences in the effects of T+O on lung function in patients with COPD. METHODS: In this Tonado(®) subgroup analysis, we assessed efficacy and safety of T+O in Japanese participants...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/27405723/development-of-an-enhanced-health-economic-model-and-cost-effectiveness-analysis-of-tiotropium-olodaterol-respimat%C3%A2-fixed-dose-combination-for-chronic-obstructive-pulmonary-disease-patients-in-italy
#12
Carl Selya-Hammer, Nuria Gonzalez-Rojas Guix, Michael Baldwin, Andrew Ternouth, Marc Miravitlles, Maureen Rutten-van Mölken, Lucas M A Goosens, Nasuh Buyukkaramikli, Valentina Acciai
BACKGROUND: The objective of this study was to compare the cost-effectiveness of the fixed-dose combination (FDC) of tiotropium + olodaterol Respimat(®) FDC with tiotropium alone for patients with chronic obstructive pulmonary disease (COPD) in the Italian health care setting using a newly developed patient-level Markov model that reflects the current understanding of the disease. METHODS: While previously published models have largely been based around a cohort approach using a Markov structure and GOLD stage stratification, an individual-level Markov approach was selected for the new model...
October 2016: Therapeutic Advances in Respiratory Disease
https://www.readbyqxmd.com/read/27383762/evaluation-of-the-effects-of-olodaterol-on-exercise-endurance-in-patients-with-chronic-obstructive-pulmonary-disease-results-from-two-6-week-crossover-studies
#13
François Maltais, Anne-Marie Kirsten, Alan Hamilton, Dorothy De Sousa, Florian Voß, Marc Decramer
BACKGROUND: Two replicate, double-blind, placebo-controlled, 6-week crossover studies assessed the effect of the once-daily long-acting β2-agonist olodaterol 5 μg and 10 μg on constant work-rate cycle endurance in patients with moderate to very severe chronic obstructive pulmonary disease. METHODS: Patients received placebo, olodaterol 5 μg once daily (QD) and olodaterol 10 μg QD in a randomised order for 6 weeks each, with a 2-week washout period in between...
July 6, 2016: Respiratory Research
https://www.readbyqxmd.com/read/27354040/olodaterol-for-the-treatment-of-chronic-obstructive-pulmonary-disease
#14
REVIEW
Wijdan H Ramadan, Wissam K Kabbara, Rosa M Abilmona
PURPOSE: Published data on the pharmacology, pharmacokinetics, efficacy, and safety of the once-daily, long-acting β2-agonist (LABA) olodaterol are reviewed. SUMMARY: Olodaterol (Striverdi Respimat, Boehringer Ingelheim), a LABA with high selectivity for β2-adrenergic receptors, is indicated for the treatment of chronic obstructive pulmonary disease (COPD); the recommended dose is 5 μg, to be delivered once daily via the Respimat inhaler. In 48- and 6-week Phase III clinical trials of olodaterol evaluating various lung function and symptomatic outcomes in patients with moderate to very severe COPD, olodaterol use was associated with significant improvements in spirometry outcomes, such as postbronchodilator forced expiratory volume in one second (FEV1), as well as dyspnea severity and quality-of-life measures...
August 1, 2016: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/27316465/effects-of-tiotropium%C3%A2-%C3%A2-olodaterol-versus-tiotropium-or-placebo-by-copd-disease-severity-and-previous-treatment-history-in-the-otemto%C3%A2-studies
#15
Dave Singh, Mina Gaga, Olaf Schmidt, Leif Bjermer, Lars Grönke, Florian Voß, Gary T Ferguson
BACKGROUND: As lung function declines rapidly in the early stages of chronic obstructive pulmonary disease (COPD), the effects of bronchodilators in patients with moderate disease and those who have not previously received maintenance therapy are of interest. OTEMTO® 1 and 2 were two replicate, 12-week, Phase III studies investigating the benefit of tiotropium + olodaterol on lung function and quality of life in patients with moderate to severe disease. Post hoc analyses were performed to assess the benefits for patients according to disease severity and treatment history...
June 18, 2016: Respiratory Research
https://www.readbyqxmd.com/read/27254953/-lama-laba-fixed-dose-combination-for-treatment-of-copd
#16
REVIEW
Ichiro Kuwahira
Several new fixed-dose combination bronchodilators have been launched in the world, and 3 different types are now available in Japan. Assessing their efficacy relative to each other has not been performed yet. In the present manuscript, characteristics of glycopyrronium/indacaterol, umeclidinium/vilanterol and tiotropium/olodaterol were reviewed. In particular, changes in trough and peak forced expiratory volume in 1 second (FEV1), St George's Respiratory Questionnaire (SGRQ) total scores, and transitional dyspnea index (TDI) focal scores were reviewed in these bronchodilators...
May 2016: Nihon Rinsho. Japanese Journal of Clinical Medicine
https://www.readbyqxmd.com/read/27254952/-role-of-bronchodilators-in-therapy-for-copd-mechanisms-of-laba-and-lama-on-airway-smooth-muscle
#17
REVIEW
Hiroaki Kume
Long-acting β2-adrenergic receptor agonists (LABAs) and anticholinergics (LAMAs) are widely used clinically as therpy for COPD. Clinical reports have demonstrated that LABAs (salmeterol, formoterol, indacaterol, olodaterol, vilanterol) and LAMAs (tiotropium, glycopyrronium, umeclidinium, aclidinium) are useful to improving symptoms and lung function, and to reducing exacerbation and hospitarization. LABAs expect salmeterol are strong partial agonists, and LAMAs are non-specific antagonists. Ca2+ dynamics and Ca2+ sensitization contribute to relaxation of airway smooth muscle in these bronchodilators...
May 2016: Nihon Rinsho. Japanese Journal of Clinical Medicine
https://www.readbyqxmd.com/read/27223863/efficacy-and-safety-of-laba-lama-fixed-dose-combinations-approved-in-the-us-for-the-management-of-copd
#18
Donald Banerji, Donald A Mahler, Nicola A Hanania
INTRODUCTION: Long-acting β2-agonists [LABAs] and long-acting muscarinic antagonists [LAMAs]) are primary therapies for chronic obstructive pulmonary disease (COPD). Despite improvements in lung function and patient-reported outcomes (PROs) with these therapies, there is room to optimize outcomes further. Combined use of LABAs and LAMAs is recommended when symptoms are not improved with a single agent, and LABA/LAMA fixed-dose combinations (FDCs) are at the forefront of drug development in COPD...
July 2016: Expert Review of Respiratory Medicine
https://www.readbyqxmd.com/read/27217742/impact-of-tiotropium-olodaterol-on-physical-functioning-in-copd-results-of-an-open-label-observational-study
#19
Rüdiger Sauer, Michaela Hänsel, Roland Buhl, Roman A Rubin, Marcel Frey, Thomas Glaab
BACKGROUND: Maintaining and improving physical functioning is key to mitigating the cycle of deconditioning associated with chronic obstructive pulmonary disease (COPD). We evaluated the impact of free combination of the long-acting anticholinergic tiotropium plus the long-acting β2-agonist olodaterol on physical functioning in a real-world clinical setting. METHODS: In this open-label noninterventional study, Global initiative for chronic Obstructive Lung Disease (GOLD) B-D patients with COPD aged ≥40 years were treated for 4-6 weeks with either tiotropium 5 μg + olodaterol 5 μg (both via Respimat(®) inhaler) or tiotropium 18 μg (HandiHaler(®)) + olodaterol 5 μg (Respimat(®)) once daily...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/27186621/olodaterol-striverdi-respimat-copd-just-another-beta-2-agonist
#20
(no author information available yet)
No abstract text is available yet for this article.
April 2016: Prescrire International
keyword
keyword
46298
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"